Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111

Oncolytic herpes simplex viruses (HSV) hold promise for therapy of glioblastoma multiforme (GBM) resistant to traditional therapies. We examined the ability of genetically engineered HSV to infect and kill cells that express CD133, a putative marker of glioma progenitor cells (GPC), to determine if...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Neurooncol
Autors principals: Friedman, Gregory K., Langford, Catherine P., Coleman, Jennifer M., Cassady, Kevin A., Parker, Jacqueline N., Markert, James M., Gillespie, G. Yancey
Format: Artigo
Idioma:Inglês
Publicat: 2009
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4574288/
https://ncbi.nlm.nih.gov/pubmed/19521665
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-009-9926-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars